Chrysin Cancer Research Results

CHr, Chrysin: Click to Expand ⟱
Features:
Chrysin is found in passion flower and honey. It is a flavonoid.
-To reach plasma levels that might more closely match the concentrations used in in vitro studies (typically micromolar), considerably high doses or advanced delivery mechanisms would be necessary.
Chrysin is widely summarized as modulating PI3K/Akt and MAPK pathways in cancer.

Chrysin — Chrysin is a naturally occurring flavone-class flavonoid found in honey, propolis, passionflower, and several plants. Its oncology relevance is mainly preclinical: it shows multi-pathway anticancer activity in cell and animal models, but native oral chrysin has very poor systemic bioavailability and no established approved oncology use.

Primary mechanisms (ranked):

  1. Suppression of PI3K/AKT survival signaling with downstream reduction in proliferation and survival programs.
  2. Induction of mitochondrial apoptosis through Bax/Bcl-2 shift, mitochondrial membrane potential loss, cytochrome c release, and caspase activation.
  3. Context-dependent ROS stress amplification in cancer cells, often linked to mitochondrial injury, ER stress, and apoptosis.
  4. ER stress / unfolded-protein-response activation leading to autophagy or stress-to-death coupling.
  5. Suppression of inflammatory, invasive, angiogenic, and metastatic signaling including NF-κB, MMPs, EMT, VEGF, and HIF-1α axes.
  6. Secondary antioxidant / NRF2-linked cytoprotection in some normal-cell or injury models, which is context-dependent and not necessarily anticancer-selective.

Bioavailability / PK relevance: Native oral chrysin has very poor systemic exposure because of low aqueous solubility, extensive intestinal/hepatic glucuronidation and sulfation, and efflux; human oral bioavailability has been reported as extremely low, often summarized as below 1%. Formulation strategies such as nanoparticles, lipid systems, micelles, cyclodextrins, or structural analogues are commonly proposed for systemic translation.

In-vitro vs systemic exposure relevance: Most anticancer studies use micromolar in-vitro concentrations that are unlikely to be reached in plasma after ordinary oral chrysin. Local intestinal exposure may be more plausible than systemic tumor exposure, but systemic anticancer claims should be treated as formulation-dependent.
LipoMicel may increase bioavailability

Clinical evidence status: Preclinical. Evidence is strong enough for mechanistic oncology interest in cell and animal models, including combination/sensitization studies, but there is no mature clinical oncology evidence establishing therapeutic benefit.

-Note half-life 2 hrs, BioAv very poor often <1%
Pathways:
Graphical Pathways

- may induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- May Lower AntiOxidant defense in Cancer Cells: NRF2↓, GSH↓ HO1↓
- May Raise AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMP2↓, MMP9↓, TIMP2, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, P53↑, HSP↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis and ATP depletion : HIF-1α↓, cMyc↓, GLUT1↓, LDH↓, HK2↓, PDKs↓, HK2↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, AMPK↓, ERK↓, JNK, TrxR,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Chrysin Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 PI3K AKT survival signaling PI3K↓; AKT phosphorylation↓; survival signaling↓ ↔ R, G Growth and survival suppression Central hub mechanism reported across multiple tumor models; also supports chemosensitization.
2 Mitochondrial apoptosis MMP↓; Bax↑; Bcl-2↓; cytochrome c↑; caspase-9/3↑ ↔ or lower sensitivity R, G Intrinsic apoptosis execution One of the most consistent anticancer endpoints, usually downstream of stress and survival-pathway suppression.
3 Mitochondrial ROS stress ROS↑ (context-dependent); oxidative stress↑; lipid peroxidation↑ ROS↓ or antioxidant protection (context-dependent) P, R, G Stress amplification Direction is dose- and model-dependent; cancer models often show pro-oxidant stress, while normal injury models may show antioxidant behavior.
4 ER stress and UPR ER stress↑; GRP78↑; UPR↑; autophagy or apoptosis↑ ↔ R, G Stress-to-death coupling Important in several chrysin cancer models and in some drug-combination effects.
5 NF-κB inflammatory transcription NF-κB↓; COX-2↓; IL-6↓; TNF-α↓ Inflammatory injury signaling↓ R, G Anti-inflammatory and anti-survival signaling May contribute to reduced proliferation, invasion, and cytokine-driven tumor support.
6 Invasion EMT and MMPs EMT↓; MMP-2↓; MMP-9↓; uPA↓; migration↓; invasion↓ ↔ G Anti-invasive phenotype Mechanistically relevant for metastasis models but generally later and context-dependent.
7 Angiogenesis and HIF-1α VEGF signaling HIF-1α↓; VEGF↓; angiogenic output↓ ↔ G Anti-angiogenic support Reported in preclinical models; may overlap with oxidative stress and DNA damage response pathways.
8 Glycolysis and metabolic stress GLUT1↓; HK2↓; LDH↓; PDK1↓; lactate production↓; ATP↓ ↔ G Metabolic suppression Relevant but less central than apoptosis and survival signaling; strongest interpretation is model-dependent.
9 NRF2 antioxidant axis NRF2↓ or antioxidant defense↓ (model-dependent) NRF2↑; SOD↑; GSH↑; catalase↑ (context-dependent) R, G Context-dependent redox selectivity Potentially useful but also interpret carefully because NRF2 activation can be protective in normal cells and sometimes undesirable in cancer cells.
10 Chemosensitization and radiosensitization Drug-induced toxicity↑; apoptosis↑; resistance signaling↓ Chemoprotection reported in some injury models G Adjunct sensitization Promising preclinical adjunct signal, but not clinically established.
11 Clinical Translation Constraint Systemic exposure low after native oral dosing Dose and formulation constraints G Translation limitation Very poor oral bioavailability is the dominant practical constraint; formulation or local GI targeting is likely required.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/physical–chemical effects; rapid signaling / phosphorylation shifts)
  • R: 30 min–3 hr (acute stress-response and redox signaling)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
Scientific Papers found: Click to Expand⟱
6126- CHr,    Chrysin induces cell apoptosis in human uveal melanoma cells via intrinsic apoptosis
- in-vitro, Melanoma, NA
tumCV↓, selectivity↑, MPT↑, Cyt‑c↑, Casp3↑, Casp9↑, Apoptosis↑, mtDam↑, chemoPv↑,
2800- CHr,    Chrysin Activates Notch1 Signaling and Suppresses Tumor Growth of Anaplastic Thyroid Carcinoma In vitro and In vivo
- in-vitro, Thyroid, NA
TumCG↓, NOTCH↑, cl‑PARP↑, Apoptosis↑,
2801- CHr,    AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells
- in-vitro, Lung, A549
AMPK↑, Akt↓, ChemoSen↑, ROS↑,
2802- CHr,    Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis
- in-vitro, Pca, DU145 - in-vivo, Pca, NA
Hif1a↓, VEGF↓, angioG↓,
2803- CHr,  5-FU,    Potentiating activities of chrysin in the therapeutic efficacy of 5-fluorouracil in gastric cancer cells
- in-vitro, GC, AGS
ChemoSen↑, TumCCA↑, eff↑, MDR1↓,
2804- CHr,  Rad,    Gamma-Irradiated Chrysin Improves Anticancer Activity in HT-29 Colon Cancer Cells Through Mitochondria-Related Pathway
- in-vitro, CRC, HT29
RadioS↑, ROS↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑,
2805- CHr,    Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC)
- in-vitro, ESCC, KYSE150 - in-vivo, ESCC, NA
FAK↓, GlucoseCon↓, Casp3↑, Casp7↑, p‑Akt↓, TumCG↓, Weight∅,
2806- CHr,  Se,    Selenium-containing chrysin and quercetin derivatives: attractive scaffolds for cancer therapy
- in-vitro, Var, NA
eff↑, selectivity↑, Dose↝, TrxR↓, GSH↓, MMP↓, ROS↑, H2O2↑,
2807- CHr,    Evidence-based mechanistic role of chrysin towards protection of cardiac hypertrophy and fibrosis in rats
- in-vivo, Nor, NA
*antiOx↑, Inflam↓, *cardioP↑, *GSH↑, *SOD↑, *Catalase↑, *GAPDH↑, *BAX↓, *Bcl-2↑, *PARP↓, *Cyt‑c↓, *Casp3↓, *NOX4↓, *NRF2↑, *HO-1↑, *HSP70/HSPA5↑,
3258- CHr,  PBG,    Chrysin Induced Cell Apoptosis and Inhibited Invasion Through Regulation of TET1 Expression in Gastric Cancer Cells
- in-vitro, GC, MKN45
TET1↑, Apoptosis↑, TumCI↓, TumCMig↓,
4260- CHr,    Chrysin modulates the BDNF/TrkB/AKT/Creb neuroplasticity signaling pathway: Acting in the improvement of cognitive flexibility and declarative, working and aversive memory deficits caused by hypothyroidism in C57BL/6 female mice
- in-vivo, NA, NA
*BDNF↑, *TrkB↑, *Akt↑, *CREB↑, *memory↑, *cognitive↑,
6122- CHr,    Disposition and metabolism of the flavonoid chrysin in normal volunteers
- Human, Nor, NA
*Dose↝, *BioAv↓,
6123- CHr,    Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms
- Review, Nor, NA
*eff↓, *BioAv↓, *eff↑, *BioAv↓, OATPs↓, MRP↓,
6124- CHr,  EGCG,    The anticancer flavonoid chrysin induces the unfolded protein response in hepatoma cells
- in-vitro, HCC, HepG2
TumCG↓, Apoptosis↓, GRP78/BiP↑, eff↑, cl‑Casp7↑, cl‑PARP↑, eff↑, UPR↑, ER Stress↑, p‑eIF2α↑, XBP-1↝, Proteasome↓,
6125- CHr,    Chrysin enhances anticancer drug-induced toxicity mediated by the reduction of claudin-1 and 11 expression in a spheroid culture model of lung squamous cell carcinoma cells
- in-vitro, SCC, NA
CLDN1↓, p‑Akt↓, ChemoSen↑,
2799- CHr,    Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-κB
- in-vivo, RCC, NA
*chemoPv↑, *ROS↓, *Inflam↓,
6127- CHr,    Chrysin Inhibits Tumor Promoter-Induced MMP-9 Expression by Blocking AP-1 via Suppression of ERK and JNK Pathways in Gastric Cancer Cells
- in-vitro, GC, AGS
AP-1↓, p‑cJun↓, p‑cFos↓, JNK↓, ERK↓, MMP9↓, TumCI↓,
6128- CHr,    Chrysin: A Comprehensive Review of Its Pharmacological Properties and Therapeutic Potential
- Review, Nor, NA - Review, Var, NA - Review, AD, NA
*antiOx↑, *Inflam↓, AntiCan↑, *neuroP↑, *ROS↓, *BioAv↓, *BioAv↑, *cardioP↑, *COX2↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *lipid-P↓, *Apoptosis↓, *NRF2↑, *HO-1↑, *MDA↓, *GSH↑, *SOD↑, *GPx↑, *GSR↑, *Catalase↑, *5HT↑, *Casp3↓, *Casp9↓, TumCCA↑, MAPK↓, PI3K↓, Akt↓, TumCP↓, TET1↑, TLR4↓, HER2/EBBR2↓, HK2↓, Glycolysis↓, glucose↓, lactateProd↓, ROS↑, mTOR↓, TumAuto↑, tumCV↓, ER Stress↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, BioAv↑,
6129- CHr,    A Chrysin Derivative Suppresses Skin Cancer Growth by Inhibiting Cyclin-dependent Kinases
- vitro+vivo, Melanoma, NA
ATP↓, TumCCA↑, CDK2↓, CDK4↓, TumW↓,
6130- CHr,    Anticancer Properties of Chrysin on Colon Cancer Cells, In vitro and In vivo with Modulation of Caspase-3, -9, Bax and Sall4
- vitro+vivo, Colon, CT26
tumCV↓, Apoptosis↑, TumVol↓, BAX↑, SALL4↓, Casp3↑, Casp9↑, ChemoSen↑, GSH↓,
6131- CHr,  Bor,  Z,    Fabrication of phenyl boronic acid modified pH-responsive zinc oxide nanoparticles as targeted delivery of chrysin on human A549 cells
- in-vitro, Lung, A549
*BioAv↑, ROS↑, TumCD↑, TumCCA↑, MMP2↓, TumMeta↓, TumCI↓, GSH↓, eff↑,
6132- CHr,  MET,    Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression
- in-vitro, BC, T47D
eff↑, cycD1/CCND1↓, hTERT/TERT↓, TumCP↓, Apoptosis↑, TumCI↓, TumMeta↓, angioG↓, selectivity↑,
6133- CHr,    Chrysin in PI3K/AKT and other apoptosis signalling pathways, and its effect on HeLa cells.
- Review, Var, NA
TumCP↓, Apoptosis↑, angioG↓, eff↑, CYP19↓, Hif1a↓, VEGF↓, NF-kB↓, PI3K↓, Akt↓,
6134- CHr,  QC,  RT,    Comparative Pharmacokinetics and Safety of a Micellar Chrysin–Quercetin–Rutin Formulation: A Randomized Crossover Trial
- Trial, Nor, NA
Dose↝, BioAv↑, MPT↑, eff↑, Half-Life↑,
6135- CHr,    Chrysin as a Multifunctional Therapeutic Flavonoid: Emerging Insights in Pathogenesis Management: A Narrative Review
- Review, Var, NA - Review, AD, NA
Inflam↓, angioG↓, Apoptosis↑, TumAuto↑, TumCCA↑, BioAv↓, Half-Life↓, BioAv↓, *ROS↓, *hepatoP↑, *RenoP↑, TET1↑, MMP9↓, cMyc↓, Ki-67↓, CBR1↓, ROS↑, ChemoSen↑, Bax:Bcl2↑, PUMA↑, NOTCH1↑, *AntiDiabetic↑, *neuroP↑, *GABA↑, *DNAdam↓, *BDNF↑, *memory↑, *AGEs↓, *Aβ↓, *cardioP↑, *AntiArt↑, eff↑, eff↑, *eff↑, RadioS↑, eff↑, ChemoSen↑, eff↑,
6136- CHr,  Tras,    Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cells
- in-vitro, BC, SkBr3 - in-vitro, BC, BT474 - in-vitro, Nor, MCF10
eff↑, HER2/EBBR2↓, p‑STAT3↓, PD-L1↓, ChemoSen↑,
6137- CHr,    Effects of Chrysin and Its Major Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide on Cytochrome P450 Enzymes and on OATP, P-gp, BCRP, and MRP2 Transporters
- in-vitro, NA, NA
CYP2C9↓, OATPs↓, ABCG2↓, BioEnh↝,
6138- CHr,  Cisplatin,    Chrysin protects against cisplatin-induced colon. toxicity via amelioration of oxidative stress and apoptosis: Probable role of p38MAPK and p53
- in-vivo, Nor, NA
*toxicity↝, eff↑, chemoP↑, *ROS↓, *MAPK↑, *P53↑, GSH↓,
6139- CHr,    Chrysin and its nanoformulations in cancer therapy: A systematic review of their radiosensitizing, phototherapy-enhancing potentials
- Review, Var, NA
RadioS↑, PhotoS↑, ROS↑, DNAdam↑, TumCCA↑, TumCD↑, selectivity↑, *ROS↓, *Inflam↓, *DNAdam↓, *antiOx↑, *lipid-P↓, *BioAv↑, eff↑, GSH↓, Catalase↓, ALAT↓, Ca+2↓, MDA↑,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
953- CHr,    Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization
- in-vivo, NA, NA
Hif1a↓, VEGF↓,
1033- CHr,    Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression
- vitro+vivo, HCC, NA
TumCG↓, CD4+↑, CD8+↑, PD-L1↓,
1107- CHr,    Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway
- in-vitro, BC, NA
TumCP↓, Apoptosis↑, MMP-10↓, E-cadherin↑, Vim↓, Snail↓, Slug↓, EMT↓,
1143- CHr,    Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2
- in-vitro, HCC, HepG2 - in-vivo, NA, NA - in-vitro, HCC, HepG3 - in-vitro, HCC, HUH7
HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, Apoptosis↑,
1144- CHr,    8-bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK
- in-vitro, HCC, HepG2 - in-vitro, HCC, Bel-7402 - in-vitro, Nor, HL7702
Casp3↑, *ROS∅, ROS↑, JNK↑, *toxicity↓,
1145- CHr,    Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways
- in-vitro, Cerv, HeLa
tumCV↓, BAX↑, BID↑, BOK↑, APAF1↑, TNF-α↑, FasL↑, Fas↑, FADD↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, Mcl-1↓, NAIP↓, Bcl-2↓, CDK4↓, CycB/CCNB1↓, cycD1/CCND1↓, cycE1↓, TRAIL↑, p‑Akt↓, Akt↓, mTOR↓, PDK1↓, BAD↓, GSK‐3β↑, AMPK↑, p27↑, P53↑,
1249- CHr,    Chrysin as an Anti-Cancer Agent Exerts Selective Toxicity by Directly Inhibiting Mitochondrial Complex II and V in CLL B-lymphocytes
- in-vitro, CLL, NA
ROS↑, MMP↓, ADP:ATP↑, Casp3↑, Apoptosis↑,
2590- CHr,    Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway
- in-vitro, GBM, T98G - in-vitro, GBM, U251 - in-vitro, GBM, U87MG
TumCP↓, TumCMig↓, TumCI↓, NRF2↓, HO-1↓, NADPH↓, ERK↓,
2591- CHr,  doxoR,    Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway
- in-vitro, HCC, Bel-7402
NRF2↓, ChemoSen↑, HO-1↓,
2780- CHr,    Anti-cancer Activity of Chrysin in Cancer Therapy: a Systematic Review
- Review, Var, NA
*antiOx↑, Inflam↓, *hepatoP↑, AntiCan↑, Cyt‑c↑, Casp3↑, XIAP↓, p‑Akt↓, PI3K↑, Apoptosis↑, COX2↓, FAK↓, AMPK↑, STAT3↑, MMP↓, DNAdam↑, BAX↑, Bak↑, Casp9↑, p38↑, MAPK↑, TumCCA↑, ChemoSen↑, HDAC8↓, Wnt↓, NF-kB↓, angioG↓, BioAv↓,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
2782- CHr,    Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
- Review, Var, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *hepatoP↑, *neuroP↑, *BioAv↓, *cardioP↑, *lipidLev↓, *RenoP↑, *TNF-α↓, *IL2↓, *PI3K↓, *Akt↓, *ROS↓, *cognitive↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, VEGF↓, p‑STAT3↓, TumMeta↓, TumCP↓, eff↑, eff↑, IL1β↓, IL6↓, NF-kB↓, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, ER Stress↑, Ca+2↑, TET1↑, Let-7↑, Twist↓, EMT↓, TumCCA↑, Casp3↑, Casp9↑, BAX↑, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, SHP1↑, N-cadherin↓, E-cadherin↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, RadioS↑, NOTCH1↑, NRF2↓, BioAv↑, eff↑,
2783- CHr,    Apoptotic Effects of Chrysin in Human Cancer Cell Lines
- Review, Var, NA
TumCP↓, Apoptosis↑, Casp↑, PCNA↓, p38↑, NF-kB↑, DNAdam↑, XIAP↓, Cyt‑c↑, Casp3↑, Akt↓, SCF↓, hTERT/TERT↓, COX2↓, *Inflam↓, *antiOx↑, *chemoPv↑, AR-V7?, CYP19?,
2784- CHr,    Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)
- Review, Var, NA
Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C↑, p‑STAT3↑, MMP2↓, MMP9↓, eff↑, cycD1/CCND1↓, hTERT/TERT↓, CLDN1↓, TumVol↓, OS↑, COX2↓, eff↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,
2798- CHr,    Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
HDAC↓, HDAC8↓, TumCG↓, Diff↑,
2786- CHr,    Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives
- Review, Var, NA
Apoptosis↑, TumCCA↑, angioG↓, TumCI↓, TumMeta↑, *toxicity↓, selectivity↑, chemoPv↑, *GSTs↑, *NADPH↑, *GSH↑, HDAC8↓, Hif1a↓, *ROS↓, *NF-kB↓, SCF↓, cl‑PARP↑, survivin↓, XIAP↓, Casp3↑, Casp9↑, GSH↓, ChemoSen↑, Fenton↑, P21↑, P53↑, cycD1/CCND1↓, CDK2↓, STAT3↓, VEGF↓, Akt↓, NRF2↓,
2787- CHr,    Network pharmacology unveils the intricate molecular landscape of Chrysin in breast cancer therapeutics
- Analysis, Var, MCF-7
TumCP↓, angioG↓, TumCI↓, TumMeta↓, TP53↑, Akt↓, Casp3↑, tumCV↓, TNF-α↓, BioAv↑, BioAv↑, AKT1↓,
2788- CHr,    Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action
- Review, Var, NA
*neuroP↑, *Inflam↓, *ROS↓, NF-kB↓, *PCNA↓, *COX2↓, ChemoSen↑, Hif1a↓, angioG↓, *chemoPv↑, PDGF↓, *memory↑, *RenoP↑, *PPARα↑, *lipidLev↓, *hepatoP↑, *cardioP⇅, *BioAv↓,
2789- CHr,    Anticancer Activity of Ether Derivatives of Chrysin
- Review, Var, NA
eff↑, COX2↓, PGE2↓, eff↑,
2790- CHr,    Chrysin: Pharmacological and therapeutic properties
- Review, Var, NA
*hepatoP↑, *neuroP↓, *ROS↓, *cardioP↑, *Inflam↓, eff↑, hTERT/TERT↓, cycD1/CCND1↓, MMP9↓, MMP2↓, TIMP1↑, TIMP2↑, BioAv↑, HK2↓, ROS↑, MMP↓, Casp3↑, ADP:ATP↑, Apoptosis↑, ER Stress↑, UPR↑, GRP78/BiP↝, eff↑, Ca+2↑,

Showing Research Papers: 1 to 50 of 60
Page 1 of 2 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 60

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

CBR1↓, 1,   SALL4↓, 1,  

Redox & Oxidative Stress ⓘ

Catalase↓, 1,   Fenton↑, 1,   GSH↓, 6,   H2O2↑, 1,   HO-1↓, 3,   lipid-P↑, 2,   MDA↑, 1,   NRF2↓, 6,   ROS↓, 1,   ROS↑, 16,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 2,   ATP↓, 1,   mt-ATP↓, 1,   BOK↑, 1,   MMP↓, 7,   MMP↑, 1,   MPT↑, 2,   mtDam↑, 1,   XIAP↓, 4,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   ALAT↓, 2,   AMPK↑, 3,   cMyc↓, 2,   glucose↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 4,   HK2↓, 6,   lactateProd↓, 3,   LDH↓, 1,   LDL↓, 1,   NADPH↓, 1,   PDK1↓, 3,   PDK3↑, 1,   PPARα↓, 1,  

Cell Death ⓘ

Akt↓, 9,   p‑Akt↓, 4,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 16,   BAD↓, 1,   Bak↑, 1,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   BID↑, 1,   Casp↑, 2,   Casp3↑, 14,   Casp7↑, 2,   cl‑Casp7↑, 1,   Casp8↑, 1,   Casp9↑, 7,   Cyt‑c↑, 5,   FADD↑, 1,   Fas↑, 1,   FasL↑, 1,   hTERT/TERT↓, 6,   iNOS↓, 1,   JNK↓, 1,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 1,   Mcl-1↓, 2,   NAIP↓, 1,   p27↑, 1,   p38↑, 2,   Proteasome↓, 1,   PUMA↑, 1,   survivin↓, 1,   TRAIL↑, 1,   TumCD↑, 2,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 2,  

Transcription & Epigenetics ⓘ

p‑cJun↓, 1,   PhotoS↑, 1,   tumCV↓, 5,  

Protein Folding & ER Stress ⓘ

eIF2α↑, 2,   p‑eIF2α↑, 2,   ER Stress↑, 6,   GRP78/BiP↑, 2,   GRP78/BiP↝, 1,   PERK↑, 2,   UPR↑, 5,   XBP-1↓, 1,   XBP-1↝, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 4,   P53↑, 2,   PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 3,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 4,   CDK4↓, 3,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 7,   cycE1↓, 1,   P21↑, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State ⓘ

AR-V7?, 1,   p‑cFos↓, 1,   Diff↑, 1,   EMT↓, 5,   ERK↓, 3,   GSK‐3β↑, 1,   HDAC↓, 3,   HDAC8↓, 3,   Let-7↑, 1,   mTOR↓, 4,   NOTCH↑, 1,   NOTCH1↑, 4,   PI3K↓, 3,   PI3K↑, 1,   SCF↓, 2,   SHP1↑, 1,   STAT3↓, 3,   STAT3↑, 1,   p‑STAT3↓, 2,   p‑STAT3↑, 1,   TOP1↓, 2,   TumCG↓, 5,   Wnt↓, 1,  

Migration ⓘ

AP-1↓, 1,   Ca+2↓, 1,   Ca+2↑, 4,   CDKN1C↑, 1,   CLDN1↓, 3,   E-cadherin↑, 4,   FAK↓, 2,   p‑FAK↓, 1,   Fibronectin↓, 1,   Ki-67↓, 2,   MMP-10↓, 2,   MMP2↓, 4,   MMP9↓, 5,   MMP9↑, 1,   N-cadherin↓, 1,   PDGF↓, 1,   Rho↓, 1,   ROCK1↓, 1,   Slug↓, 2,   Snail↓, 2,   TET1↑, 5,   TIMP1↑, 1,   TIMP2↑, 1,   TumCI↓, 7,   TumCMig↓, 3,   TumCP↓, 8,   TumMeta↓, 5,   TumMeta↑, 1,   Twist↓, 3,   uPA↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 10,   ATF4↑, 2,   EGFR↓, 1,   Hif1a↓, 6,   VEGF↓, 7,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 1,   MRP↓, 1,   OATPs↓, 2,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   COX2↓, 5,   COX2↑, 1,   IL10↓, 1,   IL1β↓, 3,   IL2↑, 1,   IL6↓, 2,   Inflam↓, 3,   NF-kB↓, 5,   NF-kB↑, 1,   PD-L1↓, 3,   PGE2↓, 2,   TLR4↓, 2,   TNF-α↓, 3,   TNF-α↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CYP19?, 1,   CYP19↓, 1,  

Drug Metabolism & Resistance ⓘ

ABCG2↓, 1,   BioAv↓, 4,   BioAv↑, 8,   BioEnh↝, 1,   ChemoSen↑, 12,   CYP2C9↓, 1,   Dose↝, 3,   eff↑, 28,   Half-Life↓, 2,   Half-Life↑, 1,   MDR1↓, 1,   RadioS↑, 4,   selectivity↑, 7,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   ALP↓, 1,   AR↓, 1,   EGFR↓, 1,   HER2/EBBR2↓, 2,   hTERT/TERT↓, 6,   IL6↓, 2,   Ki-67↓, 2,   LDH↓, 1,   PD-L1↓, 3,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 2,   neuroP↑, 2,   OS↑, 1,   RenoP↑, 1,   TumVol↓, 2,   TumW↓, 1,   Weight∅, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 217

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiArt↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 6,   Catalase↑, 4,   GPx↑, 2,   GSH↑, 3,   GSR↑, 1,   GSTs↑, 2,   HDL↑, 1,   HO-1↑, 2,   lipid-P↓, 2,   MDA↓, 2,   NOX4↓, 1,   NRF2↑, 2,   ROS↓, 11,   ROS∅, 1,   SOD↑, 4,  

Core Metabolism/Glycolysis ⓘ

CREB↑, 1,   GAPDH↑, 1,   lipidLev↓, 2,   NADPH↑, 1,   PPARα↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Akt↑, 1,   Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 2,   Casp9↓, 1,   Cyt‑c↓, 1,   iNOS↓, 1,   MAPK↓, 1,   MAPK↑, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 2,   P53↑, 1,   PARP↓, 1,   PCNA↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,   PTEN↑, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   IL1β↓, 1,   IL2↓, 1,   Inflam↓, 8,   NF-kB↓, 4,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

5HT↑, 1,   BDNF↑, 2,   GABA↑, 1,   TrkB↑, 1,  

Protein Aggregation ⓘ

AGEs↓, 1,   Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 7,   BioAv↑, 3,   Dose↝, 1,   eff↓, 1,   eff↑, 2,   P450↓, 1,  

Clinical Biomarkers ⓘ

AST↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 5,   cardioP⇅, 1,   chemoPv↑, 3,   cognitive↑, 2,   hepatoP↑, 6,   memory↑, 3,   neuroP↓, 1,   neuroP↑, 5,   RenoP↑, 3,   toxicity↓, 2,   toxicity↝, 2,  
Total Targets: 71

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:61  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page